KZA 3.00% 24.3¢ kazia therapeutics limited

Novogen up big in U.S!!

  1. 1,458 Posts.
    lightbulb Created with Sketch. 23
    Novogen was up 33% in the U.S overnight on big volume
    after this:-
    Yale Researchers Reveal Phenoxodiol's Unique Ability To Kill Ovarian Cancer Cells
    August 27, 2002 08:46:00 AM ET

    Marshall Edwards Inc. and Yale University Medical School To Develop Phenoxodiol for Ovarian Cancer

    WASHINGTON, Aug. 27 /PRNewswire-FirstCall/ -- Marshall Edwards Inc. (LSE-AIM: MSH), the subsidiary of pharmaceutical company, Novogen Limited NVGN, has entered into a services agreement with the Yale University School of Medicine's Department of Obstetrics and Gynecology.

    The association with Yale revolves around the recent discovery in Yale Medical School laboratories that MEI's anti-cancer drug, phenoxodiol, has a uniquely strong effect against ovarian cancer cells.

    Ovarian cancer is the fifth largest cause of death from cancer in women, and the American Cancer Society estimates that over 23,000 women will develop ovarian cancer in the U.S. each year. The treatment options and prognosis for women with late-stage ovarian cancer remain poor.

    In a search for an effective drug to treat ovarian cancer, the research team at Yale University Medical School, headed by Gil Mor M.D. Ph.D., has been screening new anti-cancer drugs for their ability to kill ovarian cancer cells, and in particular, to switch off a mechanism on which ovarian cancer cells depend for survival.

    Dr. Mor's team has reported that phenoxodiol is a highly effective drug that kills all ovarian cancer cells and does so by a unique mechanism that causes ovarian cancer cells to self-destruct.

    One of the outcomes of the Yale association will be to arrange a phase II clinical trial in patients with advanced ovarian cancer at Yale under the direction of Dr. Thomas Rutherford. This will be a multi-center trial to be conducted in conjunction with an Australian university hospital.

    Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials. After the results of these trials are submitted in a new drug application to the FDA, the FDA must approve the drug as safe and effective before marketing can take place.

    MEI, which trades on the Alternative Investment Market of the London Stock Exchange, is 95 percent owned by Novogen Limited. MEI was established to provide a commercial vehicle for Novogen's anti-cancer drug technology, the first of which is the novel anti-cancer drug phenoxodiol.

    Novogen is a pharmaceutical company based in Sydney, Australia with offices in Stamford, Connecticut. More information on phenoxodiol can be found at and

    Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Mkt cap ! $36.28M
Open High Low Value Volume
25.0¢ 25.0¢ 24.0¢ $52.37K 211.9K

Buyers (Bids)

No. Vol. Price($)
9 133537 24.0¢

Sellers (Offers)

Price($) Vol. No.
25.0¢ 10000 1
View Market Depth
Last trade - 15.51pm 17/08/2022 (20 minute delay) ?
-0.008 ( 4.00 %)
Open High Low Volume
24.5¢ 25.0¢ 24.0¢ 22805
Last updated 15.50pm 17/08/2022 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.